STOCK TITAN

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. The stock options have an exercise price of $31.37 per share, a ten-year term, and vest over four years. The RSUs also vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments. These grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
  • None.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $31.37 per share, equal to the closing price of Schrödinger’s common stock on December 13, 2023. The stock options have a ten-year term and vest over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee’s completion of each additional month of service over the 36-month period following the first anniversary of the employment start date.

The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee’s completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date.

The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company’s 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.

Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

Investor:

Allie Nicodemo

allie.nicodemo@schrodinger.com

Source: Schrödinger

Schrödinger, Inc. (Nasdaq: SDGR) reported granting non-statutory stock options and restricted stock units (RSUs) to three newly hired employees.

The company granted non-statutory stock options to purchase 1,800 shares of the company’s common stock and RSUs with respect to 2,250 shares of the company’s common stock to three newly hired employees.

The stock options have an exercise price of $31.37 per share.

The stock options have a ten-year term.

The stock options and RSUs both vest over four years, with 25 percent vesting after 12 months of continuous service and the balance vesting in successive installments.

The grants were made as a material inducement to the employees’ acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Schrodinger Inc

NASDAQ:SDGR

SDGR Rankings

SDGR Latest News

SDGR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Technology Services, Packaged Software, Manufacturing, Pharmaceutical Preparation Manufacturing
US
New York

About SDGR

schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part